Nicox faces financial difficulties after failure of ophthalmic treatment
Nicox's stock drops 15% after the failure of its glaucoma treatment in phase 3.
Published 4sem1 source
Lire en français
≈ 19s
The fact
The French biotech, based in Sophia Antipolis, seeks partners to avoid bankruptcy.
Its financial reserves could run out by the end of the year.
Click the link to read an article on the topic: